FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Chandra Belani

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Laura Q M Chow; Grace K Dy; Catherine Fortin; Ashok Gupta; Derek I Jonker; Garth Nicholas; Jong-Soon Park; Daniel Patricia; Eric I Sbar; Steven Zhang; Alex A. Adjei; Chandra P Belani; Scott A Laurie
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Monika Joshi; Ayodele Ayoola; Chandra P Belani
Small-cell lung cancer: an update on targeted therapies.
Laura Medford-Davis; Abram Recht; Chandra P Belani; Malcom Decamp; John Flickinger; John M Varlotto
Surgical management of early-stage non-small cell lung carcinoma and the present and future roles of adjuvant therapy: a review for the radiation oncologist.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Chandra Belani (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Laura Q M Chow; Grace K Dy; Catherine Fortin; Ashok Gupta; Derek I Jonker; Garth Nicholas; Jong-Soon Park; Daniel Patricia; Eric I Sbar; Steven Zhang; Alex A. Adjei; Chandra P Belani; Scott A Laurie
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Cancer chemotherapy and pharmacology 2013;71(5):1273-85.
2013: Monika Joshi; Ayodele Ayoola; Chandra P Belani
Small-cell lung cancer: an update on targeted therapies.
Advances in experimental medicine and biology 2013;779():385-404.
2012: Laura Medford-Davis; Abram Recht; Chandra P Belani; Malcom Decamp; John Flickinger; John M Varlotto
Surgical management of early-stage non-small cell lung carcinoma and the present and future roles of adjuvant therapy: a review for the radiation oncologist.
International journal of radiation oncology, biology, physics 2012;84(5):1048-57.
2012: Eric A Sherer; David B Solit; Chandra P Belani; Merrill J Egorin; Percy S Ivy; Jeffrey A Lieberman; Stephen B Manuck; Stephen R Marder; Matthew F Muldoon; Bruce G Pollock; Mark E Sale; Howard I Scher; Robert R Bies
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
Journal of pharmacokinetics and pharmacodynamics 2012;39(4):393-414.
2012: Audrey Mauguen; Matthew Nankivell; Rebecca Paulus; Michele I Saunders; William T Sause; Steven E Schild; Andrew T Turrisi; Aleksander Zajusz; Rodrigo Arriagada; David Ball; Michael Baumann; Katarzyna Behrendt; Chandra P Belani; James F Bishop; James A Bonner; Suzanne E Dahlberg; Dirk De Ruysscher; Stanley Dische; Rainer Koch; Cécile Le Péchoux; Sumithra J Mandrekar; Jean-Pierre Pignon
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(22):2788-97.
2012: Madhusmita Behera; Chandra P Belani; Zhengjia Chen; Fadlo R Khuri; Scott A Kono; Taofeek Owonikoko; Suresh S Ramalingam
Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.
Lung cancer (Amsterdam, Netherlands) 2012;77(2):331-8.
2012: Abdulateef O Aregbe; Chandra P Belani; Merrill J Egorin; Percy S Ivy; Suresh Ramalingam; Ramesh K Ramanathan; Howard I Scher; Eric A Sherer; David B Solit; Robert R Bies
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;70(1):201-5.
2012: Ayodele Ayoola; Amit Barochia; Kiran Belani; Chandra P Belani
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
Cancer investigation 2012;30(5):433-46.
2012: H A Wakelee; Chandra P Belani; Julie R Brahmer; S E Dahlberg; D H Johnson; C J Langer; M C Perry; A B Sandler; J H Schiller
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.
Lung cancer (Amsterdam, Netherlands) 2012;76(3):410-5.
2012: Cesare Gridelli; Luis Paz-Ares; Francesco Perrone; Robert Pirker; Andrea Ardizzoni; Chandra P Belani; Federico Cappuzzo; Fortunato Ciardiello; Filippo de Marinis; Luigi De Petris; Massimo Di Maio; Panagiotis Fidias; Rolf Stahel
Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.
Lung cancer (Amsterdam, Netherlands) 2012;76(3):269-79.
2012: Jussuf T Kaifi; Eric T Kimchi; Chandra P Belani; Niraj J Gusani; Kevin Staveley-O'Carroll; Jennifer W Toth; Michael F Reed
Multidisciplinary management of malignant pleural effusion.
Journal of surgical oncology 2012;105(7):731-8.
2012: Monika Joshi; Yixing Jiang; Chandra P Belani
Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation.
Expert opinion on pharmacotherapy 2012;13(5):685-97.
2012: Shivaani Kummar; Heinz-Josef Lenz; Robert Morgan; Edward M Newman; Ralph E Parchment; Shannon L Puhalla; Larry Rubinstein; Joseph E Tomaszewski; Lihua Wang; Yiping Zhang; Deborah Allen; Chandra P Belani; Jan H Beumer; Alice Chen; David R Gandara; Jiuping Ji; Brian Kiesel; Robert Kinders; James Doroshow
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1726-34.
2012: Chandra P Belani; Thomas Brodowicz; Tudor E Ciuleanu; Branka Cucevic; Fábio Franke; William J John; Maciej Krzakowski; Astra M Liepa; Jayaprakash Madhavan; Patrick Peterson; Rodryg Ramlau; Armando Santoro; Carla Visseren-Grul; Sung Hyun Yang; Christoph C Zielinski
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
The lancet oncology 2012;13(3):292-9.
2012: Barbara J Gitlitz; Susan Groshen; Philip Hoffman; Marianna Koczywas; Stephen V Liu; Suresh Ramalingam; Denice D Tsao-Wei; Everett E Vokes; Athanassios Argiris; Marc S Ballas; Chandra P Belani; Angela Davies; Martin J Edelman; David R Gandara
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(3):574-8.
2012: Joseph Chao; Vincent Chung; Angela Davies; Igor Espinoza-Delgado; David R Gandara; Barbara J Gitlitz; Charles Kunos; Derick H Lau; Heinz-Josef Lenz; Dean Lim; Jeff Longmate; Mark McNamara; Robert J Morgan; Edward M Newman; Suresh S Ramalingam; Stephen Shibata; Ronald G Stoller; Timothy W Synold; Chandra P Belani; Yun Yen
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Cancer chemotherapy and pharmacology 2012;69(3):835-43.
2012: Huali Wu; Beth A Zamboni; Yung-Jue Bang; Chandra P Belani; Robert P Edwards; David M Friedland; Lauren J Maruca; Suresh Ramalingam; Ramesh K Ramanathan; Ronald G Stoller; Sandra Strychor; William C Zamboni
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
International journal of nanomedicine 2012;7():5555-64.
2011: Elisabeth Iljas Heath; Patricia M LoRusso; Suresh S Ramalingam; Manuel Valdivieso; Xiaofei Zhou; Tatiana Besse-Hamer; Fatima Cardoso; Merrill J Egorin; Teresa Has; Leila Alland; Ahmad Awada; Chandra P Belani
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
Investigational new drugs 2011;29(6):1426-31.
2011: Suresh S Ramalingam; Karen Reckamp; Ravi Salgia; Miguel Villalona-Calero; Everett E Vokes; John J Wright; Chandra P Belani; Angela M Davies; Martin J Edelman; Barbara Gitlitz; Primo Lara; Jeffrey Longmate; David R Gandara
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(10):1741-5.
2011: William C Zamboni; Lauren J Maruca; Sandra Strychor; Beth A Zamboni; Suresh Ramalingam; Robert P Edwards; Jk Kim; Yj Bang; Hy Lee; David M Friedland; Ronald G Stoller; Chandra P Belani; Ramesh K Ramanathan
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
Journal of liposome research 2011;21(2):158-65.
2011: Suresh S Ramalingam; Ju-Whei Lee; Chandra P Belani; Seena C Aisner; Jill Kolesar; Craig Howe; Mario R Velasco; Joan H Schiller
Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1709-14.
2011: Rafat H Ansari; Mark A Socinski; Martin J Edelman; Chandra P Belani; René Gonin; Robert B Catalano; Donna M Marinucci; Robert L Comis; Coleman K Obasaju; Ruqin Chen; Matthew J Monberg; Joseph Treat
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Critical reviews in oncology/hematology 2011;78(2):162-71.
2011: James D Bortner; John P Richie; Arunangshu Das; Jason Liao; Todd M Umstead; Anne Stanley; Bruce A Stanley; Chandra P Belani; Karam El-Bayoumy
Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking.
Journal of proteome research 2011;10(3):1151-9.
2011: Ahmad A Tarhini; Chandra P Belani; James D Luketich; Athanassios Argiris; Suresh S Ramalingam; William Gooding; Arjun Pennathur; Daniel Petro; Kevin Kane; Denny Liggitt; Tony Championsmith; Xichen Zhang; Michael W Epperly; Joel S Greenberger
A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.
Human gene therapy 2011;22(3):336-42.
2011: Kyle D Holen; Chandra P Belani; George Wilding; Suresh Ramalingam; Jennifer Volkman; Ramesh K Ramanathan; Lakshmi S Vasist; Carolyn J Bowen; Jeffrey P Hodge; Mohammed M Dar; Peter T C Ho
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
Cancer chemotherapy and pharmacology 2011;67(2):447-54.
2011: Primo Lara; Jeff Longmate; Karen Reckamp; Barbara Gitlitz; Athanassios Argiris; Suresh Ramalingam; Chandra P Belani; Philip C Mack; Derick H Lau; Mariana Koczywas; John J Wright; Frances A Shepherd; Natasha B Leighl; David R Gandara
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Clinical lung cancer 2011;12(1):33-7.
2011: Giorgio V Scagliotti; Thomas Brodowicz; Frances A Shepherd; Christoph Zielinski; Johan Vansteenkiste; Christian Manegold; Lorinda Simms; Frank Fossella; Katherine Sugarman; Chandra P Belani
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(1):64-70.
2010: Ahmad Tarhini; Athanasios Kotsakis; William Gooding; Yongli Shuai; Daniel Petro; David Friedland; Chandra P Belani; Sanja Dacic; Athanassios Argiris
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(23):5900-7.
2010: Joseph Treat; Martin J Edelman; Chandra P Belani; Mark A Socinski; Matthew J Monberg; Ruqin Chen; Coleman K Obasaju
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2010;70(3):340-6.
2010: Suresh S Ramalingam; Shivaani Kummar; John Sarantopoulos; Stephen Shibata; Patricia M LoRusso; Mara Yerk; Julianne Holleran; Yan Lin; Jan H Beumer; R Donald Harvey; S Percy Ivy; Chandra P Belani; Merrill J Egorin
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(29):4507-12.
2010: Suresh S Ramalingam; Chandra P Belani; Philip C Mack; Everett E Vokes; Jeffrey Longmate; Ramaswamy Govindan; Marianna Koczywas; S Percy Ivy; David R Gandara
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(8):1279-84.
2010: Yixing Jiang; Fadlo R Khuri; Taofeek K Owonikoko; Suresh S Ramalingam; Chandra P Belani
What is the role of maintenance therapy in the treatment of non-small cell lung cancer?
Therapeutic advances in medical oncology 2010;2(4):229-35.
2010: Howard A Burris; Chandra P Belani; Peter A Kaufman; Alan N Gordon; Lee S Schwartzberg; Warren S Paroly; Seta Shahin; Lyndah Dreiling; Alan Saven
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
Journal of oncology practice / American Society of Clinical Oncology 2010;6(3):133-40.
2010: Taofeek K Owonikoko; Suresh S Ramalingam; Chandra P Belani
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(9):2496-504.
2010: Chandra P Belani
The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Cancer investigation 2010;28(4):413-23.
2010: Ramesh K Ramanathan; Merrill J Egorin; Charles Erlichman; Scot C Remick; Suresh S Ramalingam; Cynthia Naret; Julianne L Holleran; Cynthia J Teneyck; S Percy Ivy; Chandra P Belani
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(9):1520-6.
2010: Suresh S Ramalingam; Judy Foster; William Gooding; Terry Evans; Matthew Sulecki; Chandra P Belani
Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
Cancer 2010;116(5):1344-9.
2010: Suresh S Ramalingam; Chandra P Belani
Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope.
Current opinion in oncology 2010;22(2):79-85.
2010: Taofeek K Owonikoko; Suresh S Ramalingam; Beatriz Kanterewicz; Trent E Balius; Chandra P Belani; Pamela A Hershberger
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
International journal of cancer. Journal international du cancer 2010;126(3):743-55.
2010: Chandra P Belani; Jason Liao
Maintenance therapy for non-small-cell lung cancer.
Lancet 2010;375(9711):281-2.
2010: Martin J Edelman; Chandra P Belani; Mark A Socinski; Rafat H Ansari; Coleman K Obasaju; Ruqin Chen; Matthew J Monberg; Joseph Treat
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(1):110-6.
2010: Suresh S Ramalingam; Michael L Maitland; Paul Frankel; Athanassios Argiris; Marianna Koczywas; Barbara Gitlitz; Sachdev Thomas; Igor Espinoza-Delgado; Everett E Vokes; David R Gandara; Chandra P Belani
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(1):56-62.
2009: Daniel Morgensztern; Chandra P Belani
Novel cytotoxic agents.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(11 Suppl 3):S1082-3.
2009: William C Zamboni; Sandra Strychor; L Maruca; Sakkaraiappan Ramalingam; B A Zamboni; H Wu; D M Friedland; R P Edwards; R G Stoller; Chandra P Belani; Ramesh K Ramanathan
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Clinical pharmacology and therapeutics 2009;86(5):519-26.
2009: tudor ciuleanu; Thomas Brodowicz; Christoph Zielinski; Joo-Hang Kim; Maciej Krzakowski; Eckart Laack; Yi-Long Wu; Isabel Bover; Stephen Begbie; Valentina Tzekova; Branka Cucevic; Jose Rodrigues Pereira; Sung Hyun Yang; Jayaprakash Madhavan; Katherine P Sugarman; Patrick Peterson; William J John; Kurt Krejcy; Chandra P Belani
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Lancet 2009;374(9699):1432-40.
2009: Ramesh K Ramanathan; Chandra P Belani; Deepti A Singh; Michael Tanaka; Heinz-Josef Lenz; Yun Yen; Hedy L Kindler; Syma Iqbal; Jeff Longmate; Philip C Mack; Georg Lurje; Regina Gandour-Edwards; Janet Dancey; David R Gandara
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Cancer chemotherapy and pharmacology 2009;64(4):777-83.
2009: William C Zamboni; Sakkaraiappan Ramalingam; David M Friedland; Robert P Edwards; Ronald G Stoller; Sandra Strychor; Lauren Maruca; Beth A Zamboni; Chandra P Belani; Ramesh K Ramanathan
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1466-72.
2009: Suresh S Ramalingam; Chandra P Belani; Christopher Ruel; Paul Frankel; Barbara Gitlitz; Marianna Koczywas; Igor Espinoza-Delgado; David R Gandara
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(1):97-101.
2008: Chandra P Belani; Marshall T Schreeder; Ronald G Steis; Richard A Guidice; Thomas A Marsland; Elizabeth H Butler; Suresh S Ramalingam
Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
Cancer 2008;113(9):2512-7.
2008: David R Gandara; Primo Lara; Ronald Natale; Chandra P Belani
Progress in small-cell lung cancer: the lowest common denominator.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(26):4236-8.
2008: Suresh S Ramalingam; Chandra P Belani
Recent advances in the treatment of malignant pleural mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(9):1056-64.
2008: Yun Yen; Dean W Lim; Vincent Chung; Robert J Morgan; Lucille A Leong; Stephen I Shibata; Lawrence D Wagman; Stephen D Wagman; Howard Marx; Peiguo G Chu; Jeff Longmate; Heinz-Josef Lenz; Ramesh K Ramanathan; Chandra P Belani; David R Gandara
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
American journal of clinical oncology 2008;31(4):317-22.
2008: Suresh Ramalingam; Michael C Perry; Renato V La Rocca; David Rinaldi; Preston S Gable; William J Tester; Chandra P Belani
Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
Cancer 2008;113(3):542-6.
2008: Sakkaraiappan Ramalingam; Merrill J Egorin; Ramesh K Ramanathan; Scot C Remick; Rachel Sikorski; Theodore F Lagattuta; Gurkamal S Chatta; David M Friedland; Ronald G Stoller; Douglas M Potter; S Percy Ivy; Chandra P Belani
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3456-61.
2008: Arjun Pennathur; James D Luketich; Rodney J Landreneau; Julie Ward; Neil A Christie; Michael K Gibson; Matthew J Schuchert; Kristi Cooper; Stephanie R Land; Chandra P Belani
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
The Annals of thoracic surgery 2008;85(6):1930-6; discussion 1936-7.
2008: Sakkaraiappan Ramalingam; Judy Forster; Cynthia Naret; Terry Evans; Matt Sulecki; Haolan Lu; Paola Teegarden; Martin R Weber; Chandra P Belani
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(3):258-64.
2008: Mark A Socinski; Silvia Novello; Julie R Brahmer; Rafael Rosell; Jose M Sanchez; Chandra P Belani; Ramaswamy Govindan; James N Atkins; Heidi H Gillenwater; Cinta Pallares; Lesley Tye; Paulina Selaru; Richard C Chao; Giorgio V Scagliotti
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):650-6.
2008: Ramesh K Ramanathan; Merrill J Egorin; Chris H Takimoto; Scot C Remick; James Doroshow; Patricia M LoRusso; Daniel Mulkerin; Jean L Grem; Anne Hamilton; Anthony J Murgo; Douglas M Potter; Chandra P Belani; Michael J Hayes; Bin Peng; S Percy Ivy
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):563-9.
2008: Chandra P Belani; Suresh Ramalingam; Michael C Perry; Renato V LaRocca; David Rinaldi; Preston S Gable; William J Tester
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):468-73.
2008: Sakkaraiappan Ramalingam; Chandra P Belani
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
The oncologist 2008;13 Suppl 1():5-13.
2008: Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):60-5.
2007: Taofeek Owonikoko; Camille C Ragin; Chandra P Belani; Ana B Oton; William Gooding; Emanuela Taioli; Suresh S Ramalingam
Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5570-7.
2007: Rentian Feng; Ana Oton; Markus Y Mapara; Gülsüm Anderson; Chandra P Belani; Suzanne Lentzsch
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
British journal of haematology 2007;139(3):385-97.
2007: Roy S Herbst; Vincent J O'Neill; Louis Fehrenbacher; Chandra P Belani; Philip D Bonomi; Lowell Hart; Ostap Melnyk; David A Ramies; Ming Lin; Alan B Sandler
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4743-50.
2007: John V Heymach; Bruce E Johnson; Diane Prager; Edit Csada; Jaromír Roubec; Milos Pesek; Irena Spásová; Chandra P Belani; István Bodrogi; Shirish M Gadgeel; Sarah J Kennedy; Jeannie Hou; Roy S Herbst
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4270-7.
2007: Sakkaraiappan Ramalingam; Robert A Parise; Ramesh K Ramanathan; Ramesh K Ramananthan; Theodore F Lagattuta; Lori A Musguire; Ronald G Stoller; Douglas M Potter; Athanassios Argiris; James A Zwiebel; Merrill J Egorin; Chandra P Belani
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3605-10.
2007: Veena Charu; Chandra P Belani; Ahmad N Gill; Mukesh Bhatt; Dianne Tomita; Greg Rossi; Ali Ben-Jacob
Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
The oncologist 2007;12(6):727-37.
2007: Julie L Eiseman; Jianxia Guo; Ramesh K Ramanathan; Chandra P Belani; David B Solit; Howard I Scher; S Percy Ivy; Eleanor G Zuhowski; Merrill J Egorin
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2121-7.
2007: Ramesh K Ramanathan; D Lynn Kirkpatrick; Chandra P Belani; David M Friedland; Sylvan B Green; H-H Sherry Chow; Catherine A Cordova; Steven P Stratton; Elizabeth R Sharlow; Amanda Baker; Tomislav Dragovich
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2109-14.
2007: Sakkaraiappan Ramalingam; Chandra P Belani
Role of bevacizumab for the treatment of non-small-cell lung cancer.
Future oncology (London, England) 2007;3(2):131-9.
2007: Ramesh K Ramanathan; Merrill J Egorin; Julie L Eiseman; Sakkaraiappan Ramalingam; David M Friedland; Sanjiv S Agarwala; S Percy Ivy; Douglas M Potter; Gurkamal S Chatta; Eleanor G Zuhowski; Ronald G Stoller; Cynthia Naret; Jianxia Guo; Chandra P Belani
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1769-74.
2007: Jeffrey Crawford; Francisco Robert; Michael C Perry; Chandra P Belani; Denise Williams
A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(3):210-20.
2007: Sakkaraiappan Ramalingam; Chandra P Belani
Recent advances in targeted therapy for non-small cell lung cancer.
Expert opinion on therapeutic targets 2007;11(2):245-57.
2007: Coleman K Obasaju; Zhishen Ye; Antoinette J Wozniak; Chandra P Belani; Mary-Louise Keohan; Helen J Ross; Jonathan A Polikoff; David M Mintzer; Matthew J Monberg; Pasi A Janne
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Lung cancer (Amsterdam, Netherlands) 2007;55(2):187-94.
2007: Chandra P Belani; Sherry A Marts; Joan Schiller; Mark A Socinski
Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research.
Lung cancer (Amsterdam, Netherlands) 2007;55(1):15-23.
2007: Chandra P Belani; S Dakhil; David Waterhouse; C E Desch; D K Rooney; R H Clark; Matthew J Monberg; Zhishen Ye; Coleman K Obasaju
Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):110-5.
2006: Peter C Gerszten; Steven A. Burton; Chandra P Belani; Sakkaraiappan Ramalingam; David M Friedland; Cihat Ozhasoglu; Annette Quinn; Kevin J McCue; William C Welch
Radiosurgery for the treatment of spinal lung metastases.
Cancer 2006;107(11):2653-61.
2006: Ramaswamy Govindan; Ronald Natale; James L Wade Iii; Roy Herbst; Annetta Krebs; Richard Reiling; Thomas A Hensing; Antoinette J Wozniak; Chandra P Belani; Karen Kelly; Judith Ochs
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
Lung cancer (Amsterdam, Netherlands) 2006;53(3):331-7.
2006: Chandra P Belani; Jose R Pereira; Joachim von Pawel; Anna Pluzanska; Vera Gorbounova; Eckhard Kaukel; Karin Mattson; Rodryg Ramlau; Aleksandra Szczesna; Panos Fidias; Michael Millward; Frank V Fossella
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
Lung cancer (Amsterdam, Netherlands) 2006;53(2):231-9.
2006: Pasi A Janne; Antoinette J Wozniak; Chandra P Belani; Mary-Louise Keohan; Helen J Ross; Jonathan A Polikoff; David M Mintzer; Zhishen Ye; Matthew J Monberg; Coleman K Obasaju
Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(6):506-12.
2006: Heather A Wakelee; Wei Wang; Joan H Schiller; Corey J Langer; Alan B Sandler; Chandra P Belani; David H Johnson
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(5):441-6.
2006: Sanja Dacic; Melina B Flanagan; Kathleen Cieply; Sakkaraiappan Ramalingam; James D Luketich; Chandra P Belani; Samuel A Yousem
Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.
American journal of clinical pathology 2006;125(6):860-5.
2006: Kathy S Albain; Chandra P Belani; Philip Bonomi; Kenneth J O'Byrne; Joan H Schiller; Mark A Socinski
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
Clinical lung cancer 2006;7(6):417-9.
2006: Ramesh K Ramanathan; Marwan G Fakih; Sridhar Mani; Melvin Deutsch; Raymond P Perez; Mark A Ritter; Julie L Eiseman; S Percy Ivy; Donald L Trump; Chandra P Belani; Robert A Parise; Douglas M Potter; Merrill J Egorin
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Cancer chemotherapy and pharmacology 2006;57(4):465-74.
2006: Sakkaraiappan Ramalingam; John Barstis; Michael C Perry; Renato V La Rocca; Sreenivasa R Nattam; David Rinaldi; Ray Clark; Glenn M Mills; Chandra P Belani
Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(3):240-4.
2005: Chandra P Belani; Frank V Fossella
Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Cancer 2005;104(12):2766-74.
2005: Chandra P Belani
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Lung cancer (Amsterdam, Netherlands) 2005;50 Suppl 2():S3-8.
2005: Sakkaraiappan Ramalingam; Chandra P Belani
Molecularly-targeted therapies for non-small cell lung cancer.
Expert opinion on pharmacotherapy 2005;6(15):2667-79.
2005: Michal J Wolski; Ajay K Bhatnagar; John C Flickinger; Chandra P Belani; Sakkaraiappan Ramalingam; Joel S Greenberger
Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy.
Clinical lung cancer 2005;7(2):100-6.
2005: Chandra P Belani; Hak Choy; Phil Bonomi; Charles Scott; Patrick Travis; John Haluschak; Walter Curran
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5883-91.
2005: Pasi A Janne; Antoinette J Wozniak; Chandra P Belani; Mary-Louise Keohan; Helen J Ross; Jonathan A Polikoff; David M Mintzer; Loretta Taylor; Joseph Ashland; Zhishen Ye; Matthew J Monberg; Coleman K Obasaju
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
Clinical lung cancer 2005;7(1):40-6.
2005: Chandra P Belani; Suresh Ramalingam
Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity?
Clinical lung cancer 2005;7(1):8.
2005: Chandra P Belani; J S Lee; Mark A Socinski; F Robert; David Waterhouse; K Rowland; R Ansari; Rogerio Lilenbaum; R B Natale
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):1069-75.
2005: Chandra P Belani; Wei Wang; David H Johnson; Henry N Wagner; Joan Schiller; Michael Veeder; Minesh Mehta
Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3760-7.
2005: Chandra P Belani
The ANITA trial seals the deal for adjuvant therapy in non-small-cell lung cancer.
Clinical lung cancer 2005;6(6):331-2.
2005: Ramesh K Ramanathan; Donald L Trump; Julie L Eiseman; Chandra P Belani; Sanjiv S Agarwala; Eleanor G Zuhowski; Jing Lan; Douglas M Potter; S Percy Ivy; Sakkaraiappan Ramalingam; Adam Brufsky; Michael K K Wong; Susan Tutchko; Merrill J Egorin
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3385-91.
2005: M K Mohamed; Sakkaraiappan Ramalingam; Y Lin; W Gooding; Chandra P Belani
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(5):780-5.
2005: David Cella; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Anne Heyes; Judith S Ochs; Michael K Wolf; Andrea C Kay; Mark G Kris; Ronald B Natale
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2946-54.
2005: Chandra P Belani
Adjuvant and neoadjuvant therapy in non-small cell lung cancer.
Seminars in oncology 2005;32(2 Suppl 2):S9-15.
2005: Ramesh K Ramanathan; Sakkaraiappan Ramalingam; Merrill J Egorin; Chandra P Belani; Douglas M Potter; Marwan G Fakih; Laura L Jung; Sandra Strychor; Samuel A Jacobs; David M Friedland; Dong M Shin; Gurkamal S Chatta; Susan Tutchko; William C Zamboni
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2005;55(4):354-60.
2005: Chandra P Belani; Sakkaraiappan Ramalingam
Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer.
Clinical lung cancer 2005;6(5):267-8.
2005: Hiran C Fernando; Alberto de Hoyos; Rodney J Landreneau; Sebastien Gilbert; William Gooding; Percival O Buenaventura; Neil A Christie; Chandra P Belani; James D Luketich
Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates.
The Journal of thoracic and cardiovascular surgery 2005;129(3):639-44.
2005: Heather A Wakelee; Sakkaraiappan Ramalingam; Chandra P Belani
Docetaxel in advanced non-small cell lung cancer.
Expert review of anticancer therapy 2005;5(1):13-24.
2005: Heather A Wakelee; Chandra P Belani
Optimizing first-line treatment options for patients with advanced NSCLC.
The oncologist 2005;10 Suppl 3():1-10.
2005: Nancy Price; Chandra P Belani
Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Clinical lung cancer 2005;6(4):214-6.
2005: Chandra P Belani; Sakkaraiappan Ramalingam
Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Clinical lung cancer 2005;6(4):203-4.
2004: Chandra P Belani
Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
Seminars in oncology 2004;31(6 Suppl 14):25-33.
2004: Chandra P Belani; John Eckardt
Development of docetaxel in advanced non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;46 Suppl 2():S3-11.
2004: Chandra P Belani
Integration of docetaxel in the management of non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;46 Suppl 2():S1-2.
2004: Chandra P Belani
Emerging advances in the management of lung cancer.
Clinical lung cancer 2004;6 Suppl 2():S60.
2004: Chandra P Belani
Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
Clinical lung cancer 2004;6 Suppl 1():S6.
2004: Laura L Jung; Ramesh K Ramanathan; Merrill J Egorin; Ruzhi Jin; Chandra P Belani; Douglas M Potter; Sandra Strychor; Donald L Trump; Christine M Walko; Marwan G Fakih; William C Zamboni
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Cancer chemotherapy and pharmacology 2004;54(6):487-96.
2004: Hiran C Fernando; Alberto De Hoyos; Virginia R Litle; Chandra P Belani; James D Luketich
Radiofrequency ablation: identification of the ideal patient.
Clinical lung cancer 2004;6(3):149-53.
2004: Chandra P Belani; Alex A. Adjei
Combining targeted agents in lung cancer.
Clinical lung cancer 2004;6(3):138.
2004: Chandra P Belani
Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 2():S10-22.
2004: William C Zamboni; Laura L Jung; Merrill J Egorin; Douglas M Potter; David M Friedland; Chandra P Belani; Sanjiv S Agarwala; Michael M W Wong; Marwan G Fakih; Donald L Trump; Ruzhi Jin; Sandra Strychor; Michael Vozniak; Monica Troetschel; Ramesh K Ramanathan
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5058-64.
2004: Sakkaraiappan Ramalingam; Chandra P Belani
Paclitaxel for non-small cell lung cancer.
Expert opinion on pharmacotherapy 2004;5(8):1771-80.
2004: Sakkaraiappan Ramalingam; Chandra P Belani
Carboplatin/gemcitabine combination in advanced NSCLC.
Oncology (Williston Park, N.Y.) 2004;18(8 Suppl 5):21-6.
2004: Chandra P Belani; Sudeshna Adak; Seena Aisner; Philip J Stella; Nathan Levitan; David H Johnson
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
Clinical lung cancer 2004;6(1):43-7.
2004: Chandra P Belani
Neoadjuvant versus adjuvant therapy for resectable non-small-cell lung cancer.
Clinical lung cancer 2004;6(1):8.
2004: Chandra P Belani
Epidermal growth factor receptor mutations: a new insight.
Clinical lung cancer 2004;5(6):328.
2004: Sakkaraiappan Ramalingam; Tracy W Dobbs; Avi I Einzig; Slawomir Wojtowicz-Praga; Marianne Cascino; Phillip Bonomi; Chandra P Belani
Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.
Cancer chemotherapy and pharmacology 2004;53(5):439-44.
2004: Chandra P Belani; Sakkaraiappan Ramalingam
Smoking cessation and treatment outcome.
Clinical lung cancer 2004;5(5):264.
2004: Sakkaraiappan Ramalingam; Chandra P Belani
Basic treatment considerations: chemotherapy.
Hematology/oncology clinics of North America 2004;18(1):13-28.
2004: Sakkaraiappan Ramalingam; Chandra P Belani
State-of-the-art chemotherapy for advanced non-small cell lung cancer.
Seminars in oncology 2004;31(1 Suppl 1):68-74.
2004: Sakkaraiappan Ramalingam; Chandra P Belani; R Day; Beth A Zamboni; Samuel A Jacobs; JR Jett
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(2):247-51.
2004: Rebecca Weinberg; Darryl G L Kaurin; Hak Choy; Walter Curran; Robert MacRae; Jae Sung Kim; Jaechul Kim; Susan L Tucker; Philip D Bonomi; Chandra P Belani; George Starkschall
Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study.
Journal of applied clinical medical physics / American College of Medical Physics 2004;5(4):15-28.
2004: Sakkaraiappan Ramalingam; Chandra P Belani
Cyclooxygenase-2 inhibitors in lung cancer.
Clinical lung cancer 2004;5(4):245-53.
2004: Chandra P Belani; Sakkaraiappan Ramalingam
Lung cancer: looking ahead in 2004.
Clinical lung cancer 2004;5(4):200.
2003: Chandra P Belani
Clinical lung cancer indexed in Index Medicus and Medline.
Clinical lung cancer 2003;5(3):137.
2003: Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan B Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
JAMA : the journal of the American Medical Association 2003;290(16):2149-58.
2003: Sakkaraiappan Ramalingam; Chandra P Belani
Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer.
Seminars in thoracic and cardiovascular surgery 2003;15(4):438-47.
2003: Chandra P Belani
Elderly patients with advanced non-small-cell lung cancer.
Clinical lung cancer 2003;5(2):76.
2003: Frank V Fossella; Jose R Pereira; Joachim von Pawel; Anna Pluzanska; Vera Gorbounova; Eckhard Kaukel; Karin Mattson; Rodryg Ramlau; Aleksandra Szczesna; Panos Fidias; Michael Millward; Chandra P Belani
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3016-24.
2003: Chandra P Belani; John Barstis; Michael C Perry; Renato V La Rocca; Sreenivasa R Nattam; David Rinaldi; Ray Clark; Glenn M Mills
Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2933-9.
2003: Paul A Bunn; Frances A Shepherd; Alan B Sandler; Thierry Le Chevalier; Chandra P Belani; Paris A Kosmidis; Giorgio V Scagliotti; Giuseppe Giaccone
Ongoing and future trials of biologic therapies in lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S175-86.
2003: Chandra P Belani
Early-stage non-small-cell lung cancer: adjuvant versus neoadjuvant chemotherapy.
Clinical lung cancer 2003;5(1):11-2.
2003: Chandra P Belani
Gefitinib for non-small cell lung cancer: is the efficacy real?
Clinical lung cancer 2003;4(6):330.
2003: Chandra P Belani
Antinsense oligonucleotides in lung cancer: do they really make sense?
Clinical lung cancer 2003;4(5):266.
2003: Chandra P Belani
Newer cytotoxic and targeted agents are advancing the treatment of lung cancer.
Clinical lung cancer 2003;4 Suppl 2():S39.
2003: Chandra P Belani
Adjuvant therapy for surgically resected non-small-cell lung cancer: will it become a reality?
Clinical lung cancer 2003;4(4):203-4.
2002: Chandra P Belani; Corey Langer
First-line chemotherapy for NSCLC: an overview of relevant trials.
Lung cancer (Amsterdam, Netherlands) 2002;38 Suppl 4():13-9.
2002: Sakkaraiappan Ramalingam; Chandra P Belani
Taxanes for advanced non-small cell lung cancer.
Expert opinion on pharmacotherapy 2002;3(12):1693-709.
2002: Chandra P Belani
Creating a molecular classification for lung cancer.
Clinical lung cancer 2002;4(3):139.
2002: Ramesh K Ramanathan; Douglas M Potter; Chandra P Belani; Samuel A Jacobs; Stefan Gravenstein; Felix Lim; Hyoung Kim; Steven Savona; Terry Evans; Dianne Buchbarker; Mary B Simon; Jane K Depee; Donald L Trump
Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(21):4313-8.
2002: Sakkaraiappan Ramalingam; Chandra P Belani
Impact of INTACT: do we change the target or the aim?
Clinical lung cancer 2002;4(2):75.
2002: Sakkaraiappan Ramalingam; Chandra P Belani
Doublet chemotherapy for advanced non-small cell lung cancer.
Clinical lung cancer 2002;4(1):13.
2002: Chandra P Belani
Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
Seminars in oncology 2002;29(3 Suppl 12):4-9.
2002: Chandra P Belani; Ryan J Sauder
Docetaxel/platinum in advanced non-small-cell lung cancer: recent randomized trials.
Clinical lung cancer 2002;3 Suppl 2():S7-11.
2002: Ajay K Bhatnagar; John C Flickinger; Sanjeev Bahri; Melvin Deutsch; Chandra P Belani; James D Luketich; Joel S Greenberger
Update on results of multifield conformal radiation therapy of non-small-cell lung cancer using multileaf collimated beams.
Clinical lung cancer 2002;3(4):259-64.
2002: Chandra P Belani
Chemotherapy regimens in advanced non-small-cell lung cancer: recent randomized trials.
Clinical lung cancer 2002;3 Suppl 1():S5-9.
2002: Chandra P Belani
Extensive-stage small-cell lung cancer: is the progress real?
Clinical lung cancer 2002;3(3):168.
2002: Sakkaraiappan Ramalingam; Chandra P Belani
Meaningful survival in lung cancer patients.
Seminars in oncology 2002;29(1 Suppl 4):125-31.
2002: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan B Sandler; James Krook; Junming Zhu; David H Johnson
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
The New England journal of medicine 2002;346(2):92-8.
2001: Christopher J Sweeney; J Zhu; Alan B Sandler; J Schiller; Chandra P Belani; C Langer; J Krook; D Harrington; D H Johnson
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Cancer 2001;92(10):2639-47.
2001: Chandra P Belani
Lung cancer: search for a marker.
Clinical lung cancer 2001;3(2):91.
2001: Chandra P Belani
Individualized therapy for non-small cell lung cancer.
Clinical lung cancer 2001;3(1):11.
2001: Chandra P Belani
Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer.
Seminars in oncology 2001;28(4 Suppl 14):14-6.
2001: Chandra P Belani
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Seminars in oncology 2001;28(3 Suppl 9):10-4.
2001: S Shihabi; Chandra P Belani
Role of topoisomerase I inhibitors in small-cell lung cancer.
Clinical lung cancer 2001;2(4):275-81.
2001: Chandra P Belani
Targets...targets...targets... Targeted therapies in lung cancer.
Clinical lung cancer 2001;2(4):251.
2001: James D Luketich; D M Friedman; Carolyn Meltzer; Chandra P Belani; David W Townsend; Neil A Christie; Tracey L Weigel
The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small-cell lung cancer.
Clinical lung cancer 2001;2(3):229-33.
2001: Chandra P Belani; Thomas J Lynch
Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.
Seminars in oncology 2001;28(1 Suppl 2):10-4.
2001: A R Calvo; Chandra P Belani
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Cancer treatment and research 2001;105():189-227.
2000: Chandra P Belani
Chemotherapy regimens in advanced non small-cell lung cancer: recent randomized trials.
Clinical lung cancer 2000;2 Suppl 1():S7-S10.
2000: Chandra P Belani
Locally advanced, unresectable non-small cell lung cancer shift in the treatment paradigm.
Clinical lung cancer 2000;2(2):90.
2000: James D Luketich; M A Meehan; Rodney J Landreneau; Neil A Christie; John M Close; Peter F Ferson; Robert J Keenan; Chandra P Belani
Total videothoracoscopic lobectomy versus open thoracotomy for early-stage non small-cell lung cancer.
Clinical lung cancer 2000;2(1):56-60; discussion 61.
2000: Chandra P Belani
Non-small-cell lung cancer have we reached a "chemotherapy efficacy plateau"?
Clinical lung cancer 2000;2(1):10.
2000: Chandra P Belani; Avi I Einzig; Phillip Bonomi; Tracy W Dobbs; Mary Jo Capozzoli; R Earhart; L J Cohen; James D Luketich
Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(6):673-8.
2000: Joel S Greenberger; Michael W Epperly; James D Luketich; W Gooding; Chandra P Belani
Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy protection of the esophagus from chemoradiotherapy damage during treatment of locally unresectable non-small-cell lung cancer (NSCLC).
Clinical lung cancer 2000;1(4):302-4.
2000: Chandra P Belani
Clinical lung cancer - a promising start.
Clinical lung cancer 2000;1(4):249.
2000: Chandra P Belani
Docetaxel in combination with platinum compounds for non small-cell lung cancer.
Clinical lung cancer 2000;1 Suppl 1():S10-4.
2000: Chandra P Belani
Paclitaxel and docetaxel combinations in non-small cell lung cancer.
Chest 2000;117(4 Suppl 1):144S-151S.
2000: Chandra P Belani
Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations.
Chest 2000;117(4 Suppl 1):127S-132S.
2000: Ramesh K Ramanathan; Joshua Rubin; N Paul Ohori; Chandra P Belani
Dramatic response of adult wilms tumor to paclitaxel and cisplatin.
Medical and pediatric oncology 2000;34(4):296-8.
2000: Chandra P Belani
Lung cancer in the new millennium.
Clinical lung cancer 2000;1(3):169.
2000: David R Gandara; E Vokes; M Green; P Bonomi; Russell F DeVore; R Comis; D Carbone; D Karp; Chandra P Belani
Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):131-5.
1999: Hedy L Kindler; Chandra P Belani; James E Herndon; Nicholas J Vogelzang; Y Suzuki; Mark R Green
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
Cancer 1999;86(10):1985-91.
1999: Chandra P Belani; Phillip Bonomi; Tracy W Dobbs; Russell F DeVore; David S Ettinger; J Jett; James D Luketich; L J Cohen; David H Johnson
Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial.
Clinical lung cancer 1999;1(2):144-50.
1999: F Fossella; J R Rigas; Chandra P Belani
New options in the treatment of non-small cell lung cancer.
Anti-cancer drugs 1999;10 Suppl 1():S25-8.
1999: James D Luketich; Ninh T Nguyen; Tracey L Weigel; Robert J Keenan; Peter F Ferson; Chandra P Belani
Photodynamic therapy for treatment of malignant dysphagia.
Surgical laparoscopy, endoscopy & percutaneous techniques 1999;9(3):171-5.
1999: Chandra P Belani
Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments.
Seminars in oncology 1999;26(3 Suppl 10):15-8.
1999: G Selvaggi; Chandra P Belani
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Seminars in oncology 1999;26(2 Suppl 7):51-60.
1999: Chandra P Belani
Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.
Seminars in oncology 1999;26(1 Suppl 2):44-54.
1999: Chandra P Belani; C M Kearns; Eleanor G Zuhowski; K Erkmen; D Hiponia; D Zacharski; C Engstrom; Ramesh K Ramanathan; Mary Jo Capozzoli; Joseph Aisner; Merrill J Egorin
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):676-84.
1999: Sanjeev Bahri; John C Flickinger; AM Kalend; Melvin Deutsch; Chandra P Belani; Frank C Sciurba; James D Luketich; Joel S Greenberger
Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Radiation oncology investigations 1999;7(5):297-308.
1998: J Treat; E Johnson; C Langer; Chandra P Belani; B Haynes; R Greenberg; R Rodriquez; P Drobins; W Miller; L Meehan; A McKeon; J Devin; R von Roemeling; J Viallet
Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3524-7.
1998: ES Kassis; Chandra P Belani; Peter F Ferson; Robert J Keenan; James D Luketich
Hodgkin's disease presenting with a bronchoesophageal fistula.
The Annals of thoracic surgery 1998;66(4):1409-10.
1998: Arun K Rishi; M Yu; J J Tsai-Wu; Chandra P Belani; Joseph A Fontana; D L Baker; M Periasamy; Arif Hussain
Gene amplification and transcriptional upregulation of the sarco/endoplasmic reticulum Ca2+ transport ATPase in thapsigargin-resistant hamster smooth muscle cells.
Nucleic acids research 1998;26(19):4529-37.
1998: Chandra P Belani
Single agents in the second-line treatment of non-small cell lung cancer.
Seminars in oncology 1998;25(3 Suppl 8):10-4.
1998: Chandra P Belani
Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 1998;12(1 Suppl 2):74-9.
1998: Chandra P Belani; T S Pajeau; C L Bennett
Treating malignant pleural effusions cost consciously.
Chest 1998;113(1 Suppl):78S-85S.
1998: Chandra P Belani; Ramesh K Ramanathan
Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents.
Chest 1998;113(1 Suppl):53S-60S.
1998: Joel S Greenberger; Sanjeev Bahri; J Jett; Chandra P Belani; AM Kalend; Michael W Epperly
Considerations in optimizing radiation therapy for non-small cell lung cancer.
Chest 1998;113(1 Suppl):46S-52S.
1997: Chandra P Belani; J D Luketich; R J Landreaneau; R Kim; Ramesh K Ramanathan; R Day; Peter F Ferson; Robert J Keenan; M Posner; J Seeger; Barry C Lembersky
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus.
Seminars in oncology 1997;24(6 Suppl 19):S19-89-S19-92.
1997: James D Luketich; Philip R Schauer; K Urso; David W Townsend; Chandra P Belani; Carolyn Cidis Meltzer; Peter F Ferson; Robert J Keenan
Minimally invasive surgical biopsy confirms PET findings in esophageal cancer.
Surgical endoscopy 1997;11(12):1213-5.
1997: James D Luketich; Philip R Schauer; Carolyn Meltzer; Rodney J Landreneau; G K Urso; David W Townsend; Peter F Ferson; Robert J Keenan; Chandra P Belani
Role of positron emission tomography in staging esophageal cancer.
The Annals of thoracic surgery 1997;64(3):765-9.
1997: Chandra P Belani
Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 1997;11(8 Suppl 8):42-5.
1997: Ramesh K Ramanathan; Chandra P Belani
Chemotherapy for advanced non-small cell lung cancer: past, present, and future.
Seminars in oncology 1997;24(4):440-54.
1996: Chandra P Belani; Joseph Aisner; Sanjeev Bahri; J Jett; R Day; M J Capazolli; D Hiponia; C Engstrom
Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease.
Seminars in oncology 1996;23(6 Suppl 16):113-6.
1996: Chandra P Belani; Joseph Aisner; D Hiponia; Ramesh K Ramanathan
Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study.
Seminars in oncology 1996;23(5 Suppl 12):19-21.
1996: Ramesh K Ramanathan; V V Reddy; J M Holbert; Chandra P Belani
Pulmonary infiltrates following administration of paclitaxel.
Chest 1996;110(1):289-92.
1996: Ramesh K Ramanathan; Chandra P Belani
Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel.
Annals of internal medicine 1996;124(2):278.
1995: Joseph Aisner; Chandra P Belani; C Kearns; BA Conley; D Hiponia; C Engstrom; Eleanor G Zuhowski; Merrill J Egorin
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
Seminars in oncology 1995;22(5 Suppl 12):17-21.
1995: C M Kearns; Chandra P Belani; K Erkmen; M Zuhowski; D Hiponia; D Zacharski; C Engstrom; Ramesh K Ramanathan; M R Trenn; Joseph Aisner
Pharmacokinetics of paclitaxel and carboplatin in combination.
Seminars in oncology 1995;22(5 Suppl 12):1-4; discussion 5-7.
1995: L Austin Doyle; Douglas Ross; J V Ordonez; W Yang; Y Gao; Y Tong; Chandra P Belani; J C Gutheil
An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
British journal of cancer 1995;72(3):535-42.
1995: Chandra P Belani; Joseph Aisner; D Hiponia; C Engstrom
Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):7-12.
1995: J D Hainsworth; N Levitan; G L Wampler; Chandra P Belani; M S Seyedsadr; J Randolph; L P Schacter; F Anthony Greco
Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1436-42.
1995: Joseph Aisner; D Hiponia; BA Conley; M Jacobs; W Gray; Chandra P Belani
Combined modalities in the treatment of head and neck cancers.
Seminars in oncology 1995;22(3 Suppl 6):28-34.
1995: Charles S White; Linda B Haramati; K H Elder; J Karp; Chandra P Belani
Carcinoma of the lung in HIV-positive patients: findings on chest radiographs and CT scans.
AJR. American journal of roentgenology 1995;164(3):593-7.
1995: Everett E Vokes; R K Rosenberg; M Jahanzeb; J B Craig; R J Gralla; Chandra P Belani; S E Jones; J W Bigley; JA Hohneker
Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):637-44.
1994: Everett E Vokes; R Rosenberg; M Jahanzeb; J Craig; R Gralla; Chandra P Belani; S Jones; J Bigley; JA Hohneker
Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report.
Seminars in oncology 1994;21(5 Suppl 10):35-8; discussion 38-41.
1994: Chandra P Belani; Joseph Aisner
Combined chemotherapy and radiation in locally advanced non-small cell lung cancer.
Seminars in oncology 1994;21(3 Suppl 6):79-90.
1994: J F Flores; Robert K Rude; Robert A Chapman; Chandra P Belani; A Y Chang; J D Pritchard; J V Hoff
Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
Cancer 1994;73(10):2527-34.
1994: P J Hollen; R J Gralla; Mark G Kris; Christopher Cox; Chandra P Belani; S M Grunberg; Jeffrey Crawford; J A Neidhart
Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.
Cancer 1994;73(8):2087-98.
1994: J C Gutheil; S R Hart; Chandra P Belani; Peter W Melera; Arif Hussain
Alterations in Ca2+ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin.
The Journal of biological chemistry 1994;269(11):7976-81.
1994: N M Bleehen; D Ball; Chandra P Belani; J Bishop; J Y Douillard; J D Cox; D H Johnson; T Le Chevalier; M I Saunders; E Shaw
Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma.
Lung cancer (Amsterdam, Netherlands) 1994;10 Suppl 1():S19-23.
1994: J Cox; D Ball; Chandra P Belani; N Choi; R Gralla; J Halle; R Komaki; T Le Chevalier; T Ohnoshi; Elisabeth Quoix
Dose intensity in lung cancer treatment.
Lung cancer (Amsterdam, Netherlands) 1994;10 Suppl 1():S11-3.
1994: Chandra P Belani; Anne Belcher; R Sridhara; Stephen C Schimpff
Instruction in the techniques and concept of supportive care in oncology.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(1):50-5.
1994: Chandra P Belani; L Austin Doyle; Joseph Aisner
Etoposide: current status and future perspectives in the management of malignant neoplasms.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S118-26.
1993: Chandra P Belani
Multimodality management of regionally advanced non-small-cell lung cancer.
Seminars in oncology 1993;20(4):302-14.
1993: Joseph Aisner; Chandra P Belani
Lung cancer: recent changes and expectations of improvements.
Seminars in oncology 1993;20(4):383-93.
1993: J S Abrams; Julie L Eiseman; T J Melink; R Sridhara; D J Hiponia; M M Bell; Chandra P Belani; W H Adler; Joseph Aisner
Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(1):56-64.
1993: Charles S White; PA Templeton; Chandra P Belani
Imaging in lung cancer.
Seminars in oncology 1993;20(2):142-52.
1992: Chandra P Belani; Joseph Aisner
Combined-modality therapies for non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 3():3-10.
1992: F Kruter; Mario A Eisenberger; Victoria Sinibaldi; C Engstrom; M Jacobs; J Abrams; Chandra P Belani; W Gray; S Krasnow
Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck.
Investigational new drugs 1992;10(2):89-91.
1990: Chandra P Belani; Joseph Aisner
Therapy for small cell and non-small cell lung cancer.
Current opinion in oncology 1990;2(2):334-44.
1989: Chandra P Belani; Merrill J Egorin; J S Abrams; D Hiponia; Mario A Eisenberger; Joseph Aisner; David A Van Echo
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1896-902.
1989: Chandra P Belani; David A Van Echo; Joseph Aisner
Platinum compounds.
Current opinion in oncology 1989;1(2):186-91.
1989: N O Whitley; Chandra P Belani; Joseph Aisner; A Forrest; J Whitley
Tumor volume and treatment outcome in small cell lung carcinoma.
Investigative radiology 1989;24(8):581-4.
1989: Merrill J Egorin; A Forrest; Chandra P Belani; M J Ratain; J S Abrams; David A Van Echo
A limited sampling strategy for cyclophosphamide pharmacokinetics.
Cancer research 1989;49(11):3129-33.
1989: Chandra P Belani; P Pearl; N O Whitley; Joseph Aisner
Tamoxifen withdrawal response. Report of a case.
Archives of internal medicine 1989;149(2):449-50.
1988: Chandra P Belani; Mario A Eisenberger; W C Gray
Preliminary experience with chemotherapy in advanced salivary gland neoplasms.
Medical and pediatric oncology 1988;16(3):197-202.
1987: Chandra P Belani; Mario A Eisenberger; David A Van Echo; D Hiponia; Joseph Aisner
Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.
Cancer treatment reports 1987;71(11):1099-100.
1986: R A Berg; A Belani; Chandra P Belani
Vasculitis in a suspected AIDS patient.
Southern medical journal 1986;79(7):914-5.